Logo image of CCEL

CRYO-CELL INTL INC (CCEL) Stock Fundamental Analysis

NYSEARCA:CCEL - NYSE Arca - US2288951088 - Common Stock - Currency: USD

7.1726  +0.14 (+2.03%)

Fundamental Rating

3

Overall CCEL gets a fundamental rating of 3 out of 10. We evaluated CCEL against 107 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of CCEL while its profitability can be described as average. CCEL is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year CCEL has reported negative net income.
CCEL had a positive operating cash flow in the past year.
Of the past 5 years CCEL 4 years were profitable.
In the past 5 years CCEL always reported a positive cash flow from operatings.
CCEL Yearly Net Income VS EBIT VS OCF VS FCFCCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M

1.2 Ratios

The Return On Assets of CCEL (-14.18%) is worse than 75.93% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.40%, CCEL is in the better half of the industry, outperforming 76.85% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CCEL is in line with the industry average of 8.16%.
Industry RankSector Rank
ROA -14.18%
ROE N/A
ROIC 8.4%
ROA(3y)-2.62%
ROA(5y)1.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)9.24%
ROIC(5y)15.06%
CCEL Yearly ROA, ROE, ROICCCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

1.3 Margins

With an excellent Operating Margin value of 14.38%, CCEL belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
In the last couple of years the Operating Margin of CCEL has declined.
With an excellent Gross Margin value of 73.66%, CCEL belongs to the best of the industry, outperforming 90.74% of the companies in the same industry.
CCEL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 14.38%
PM (TTM) N/A
GM 73.66%
OM growth 3Y-20.39%
OM growth 5Y-3.99%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.93%
GM growth 5Y0.64%
CCEL Yearly Profit, Operating, Gross MarginsCCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

CCEL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for CCEL has been reduced compared to 1 year ago.
CCEL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CCEL has a worse debt to assets ratio.
CCEL Yearly Shares OutstandingCCEL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
CCEL Yearly Total Debt VS Total AssetsCCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 0.45, we must say that CCEL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.45, CCEL is not doing good in the industry: 71.30% of the companies in the same industry are doing better.
CCEL has a debt to FCF ratio of 2.75. This is a good value and a sign of high solvency as CCEL would need 2.75 years to pay back of all of its debts.
CCEL's Debt to FCF ratio of 2.75 is fine compared to the rest of the industry. CCEL outperforms 79.63% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.75
Altman-Z 0.45
ROIC/WACC0.84
WACC10.06%
CCEL Yearly LT Debt VS Equity VS FCFCCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M -15M

2.3 Liquidity

A Current Ratio of 0.61 indicates that CCEL may have some problems paying its short term obligations.
With a Current ratio value of 0.61, CCEL is not doing good in the industry: 88.89% of the companies in the same industry are doing better.
A Quick Ratio of 0.57 indicates that CCEL may have some problems paying its short term obligations.
CCEL has a worse Quick ratio (0.57) than 84.26% of its industry peers.
Industry RankSector Rank
Current Ratio 0.61
Quick Ratio 0.57
CCEL Yearly Current Assets VS Current LiabilitesCCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CCEL have decreased strongly by -453.33% in the last year.
Looking at the last year, CCEL shows a small growth in Revenue. The Revenue has grown by 1.94% in the last year.
The Revenue has been growing slightly by 1.41% on average over the past years.
EPS 1Y (TTM)-453.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)1.94%
Revenue growth 3Y0.21%
Revenue growth 5Y1.41%
Sales Q2Q%2.49%

3.2 Future

Based on estimates for the next years, CCEL will show a very strong growth in Earnings Per Share. The EPS will grow by 30.17% on average per year.
The Revenue is expected to grow by 1.15% on average over the next years.
EPS Next Y125.95%
EPS Next 2Y43.93%
EPS Next 3Y30.17%
EPS Next 5YN/A
Revenue Next Year2.15%
Revenue Next 2Y1.23%
Revenue Next 3Y1.15%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CCEL Yearly Revenue VS EstimatesCCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M
CCEL Yearly EPS VS EstimatesCCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CCEL. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 87.90, which means the current valuation is very expensive for CCEL.
CCEL's Price/Forward Earnings ratio is in line with the industry average.
CCEL is valuated expensively when we compare the Price/Forward Earnings ratio to 22.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 87.9
CCEL Price Earnings VS Forward Price EarningsCCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

64.81% of the companies in the same industry are more expensive than CCEL, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, CCEL is valued a bit cheaper than 71.30% of the companies in the same industry.
Industry RankSector Rank
P/FCF 18.77
EV/EBITDA 11.64
CCEL Per share dataCCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CCEL's earnings are expected to grow with 30.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.93%
EPS Next 3Y30.17%

More info and screens

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 14.22%, CCEL is a good candidate for dividend investing.
CCEL's Dividend Yield is rather good when compared to the industry average which is at 3.11. CCEL pays more dividend than 99.07% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.33, CCEL pays a better dividend.
Industry RankSector Rank
Dividend Yield 14.22%

5.2 History

CCEL has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
CCEL Yearly Dividends per shareCCEL Yearly Dividends per shareYearly Dividends per share 2022 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

DP0%
EPS Next 2Y43.93%
EPS Next 3Y30.17%
CCEL Yearly Income VS Free CF VS DividendCCEL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M

More info and screens

CRYO-CELL INTL INC

NYSEARCA:CCEL (3/7/2025, 8:10:30 PM)

7.1726

+0.14 (+2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)04-14 2025-04-14/amc
Inst Owners7.71%
Inst Owner Change14.42%
Ins Owners40.27%
Ins Owner Change1.01%
Market Cap57.95M
Analysts82.86
Price Target9.18 (27.99%)
Short Float %0.41%
Short Ratio1.14
Dividend
Industry RankSector Rank
Dividend Yield 14.22%
Yearly Dividend0.9
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-14 2025-02-14 (0.25)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)316.67%
Min EPS beat(2)96.08%
Max EPS beat(2)537.26%
EPS beat(4)3
Avg EPS beat(4)-175.07%
Min EPS beat(4)-1776.75%
Max EPS beat(4)537.26%
EPS beat(8)7
Avg EPS beat(8)72.25%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.18%
Min Revenue beat(2)-1.39%
Max Revenue beat(2)-0.96%
Revenue beat(4)0
Avg Revenue beat(4)-1.92%
Min Revenue beat(4)-2.95%
Max Revenue beat(4)-0.96%
Revenue beat(8)2
Avg Revenue beat(8)-0.25%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 87.9
P/S 1.82
P/FCF 18.77
P/OCF 8.05
P/B N/A
P/tB N/A
EV/EBITDA 11.64
EPS(TTM)-1.06
EYN/A
EPS(NY)0.08
Fwd EY1.14%
FCF(TTM)0.38
FCFY5.33%
OCF(TTM)0.89
OCFY12.42%
SpS3.94
BVpS-1.18
TBVpS-1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.18%
ROE N/A
ROCE 10.06%
ROIC 8.4%
ROICexc 8.81%
ROICexgc 9.44%
OM 14.38%
PM (TTM) N/A
GM 73.66%
FCFM 9.7%
ROA(3y)-2.62%
ROA(5y)1.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)9.24%
ROIC(5y)15.06%
ROICexc(3y)10.39%
ROICexc(5y)20.13%
ROICexgc(3y)11.45%
ROICexgc(5y)23.43%
ROCE(3y)11.07%
ROCE(5y)18.04%
ROICexcg growth 3Y-39.1%
ROICexcg growth 5Y-16.64%
ROICexc growth 3Y-37.06%
ROICexc growth 5Y-14.93%
OM growth 3Y-20.39%
OM growth 5Y-3.99%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.93%
GM growth 5Y0.64%
F-Score6
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.75
Debt/EBITDA 1.55
Cap/Depr 526.42%
Cap/Sales 12.91%
Interest Coverage 2.38
Cash Conversion 134.28%
Profit Quality N/A
Current Ratio 0.61
Quick Ratio 0.57
Altman-Z 0.45
F-Score6
WACC10.06%
ROIC/WACC0.84
Cap/Depr(3y)492.66%
Cap/Depr(5y)333.98%
Cap/Sales(3y)22.77%
Cap/Sales(5y)14.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-453.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y125.95%
EPS Next 2Y43.93%
EPS Next 3Y30.17%
EPS Next 5YN/A
Revenue 1Y (TTM)1.94%
Revenue growth 3Y0.21%
Revenue growth 5Y1.41%
Sales Q2Q%2.49%
Revenue Next Year2.15%
Revenue Next 2Y1.23%
Revenue Next 3Y1.15%
Revenue Next 5YN/A
EBIT growth 1Y7.06%
EBIT growth 3Y-20.23%
EBIT growth 5Y-2.63%
EBIT Next Year188.1%
EBIT Next 3Y41.86%
EBIT Next 5YN/A
FCF growth 1Y166.07%
FCF growth 3Y-37.11%
FCF growth 5Y-14.99%
OCF growth 1Y-7.84%
OCF growth 3Y1.75%
OCF growth 5Y10.83%